399 related articles for article (PubMed ID: 37040283)
1. Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy.
Fang C; Xiao G; Wang T; Song L; Peng B; Xu B; Zhang K
Research (Wash D C); 2023; 6():0108. PubMed ID: 37040283
[TBL] [Abstract][Full Text] [Related]
2. Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy.
Ban W; Guan J; Huang H; He Z; Sun M; Liu F; Sun J
Nano Res; 2022; 15(5):4137-4153. PubMed ID: 35194488
[TBL] [Abstract][Full Text] [Related]
3. Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy.
Zhang T; Jou TH; Hsin J; Wang Z; Huang K; Ye J; Yin H; Xing Y
J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769745
[TBL] [Abstract][Full Text] [Related]
4. The Role of Oncolytic Viruses in the Treatment of Melanoma.
Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Viruses in Cancer Treatment: A Review.
Lawler SE; Speranza MC; Cho CF; Chiocca EA
JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in oncolytic virus-based cancer therapy.
Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
[TBL] [Abstract][Full Text] [Related]
7. Review: Oncolytic virotherapy, updates and future directions.
Fountzilas C; Patel S; Mahalingam D
Oncotarget; 2017 Nov; 8(60):102617-102639. PubMed ID: 29254276
[TBL] [Abstract][Full Text] [Related]
8. Therapy with oncolytic viruses: progress and challenges.
Shalhout SZ; Miller DM; Emerick KS; Kaufman HL
Nat Rev Clin Oncol; 2023 Mar; 20(3):160-177. PubMed ID: 36631681
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
10. The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.
Eissa IR; Bustos-Villalobos I; Ichinose T; Matsumura S; Naoe Y; Miyajima N; Morimoto D; Mukoyama N; Zhiwen W; Tanaka M; Hasegawa H; Sumigama S; Aleksic B; Kodera Y; Kasuya H
Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30261620
[TBL] [Abstract][Full Text] [Related]
11. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
[TBL] [Abstract][Full Text] [Related]
12. Past, Present and Future of Oncolytic Reovirus.
Müller L; Berkeley R; Barr T; Ilett E; Errington-Mais F
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33142841
[TBL] [Abstract][Full Text] [Related]
13. Immune System, Friend or Foe of Oncolytic Virotherapy?
Filley AC; Dey M
Front Oncol; 2017; 7():106. PubMed ID: 28589085
[TBL] [Abstract][Full Text] [Related]
14. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on immunotherapy via oncolytic viruses.
Reale A; Vitiello A; Conciatori V; Parolin C; Calistri A; Palù G
Infect Agent Cancer; 2019; 14():5. PubMed ID: 30792754
[TBL] [Abstract][Full Text] [Related]
16. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?
Zhang S; Rabkin SD
Expert Opin Drug Discov; 2021 Apr; 16(4):391-410. PubMed ID: 33232188
[No Abstract] [Full Text] [Related]
17. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.
Yun CO; Hong J; Yoon AR
Front Immunol; 2022; 13():953410. PubMed ID: 36091031
[TBL] [Abstract][Full Text] [Related]
18. Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy.
Reale A; Calistri A; Altomonte J
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959474
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
[TBL] [Abstract][Full Text] [Related]
20. Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers.
Ziogas DC; Martinos A; Petsiou DP; Anastasopoulou A; Gogas H
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]